summary
Introduced
07/18/2023
07/18/2023
In Committee
07/18/2023
07/18/2023
Crossed Over
Passed
Dead
01/03/2025
01/03/2025
Introduced Session
118th Congress
Bill Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical drugs of increased demand, and for other purposes.
AI Summary
This bill, the Drug Shortage Prevention Act of 2023, aims to improve notification procedures when there is an increased demand for critical drugs. It amends the Federal Food, Drug, and Cosmetic Act to require manufacturers of "covered drugs" (life-supporting, life-sustaining, or drugs critical for public health emergencies) to notify the Secretary of Health and Human Services of any permanent discontinuance, interruption in manufacturing, or other circumstances that could lead to a meaningful disruption in the drug supply. The bill also requires manufacturers to provide additional details on the reasons for the disruption, such as the source of active pharmaceutical ingredients. Additionally, the bill amends reporting requirements for drug manufacturers to provide more information on their supply chains and suppliers of active pharmaceutical ingredients and other materials.
Committee Categories
Health and Social Services
Sponsors (7)
Amy Klobuchar (D)*,
Susan Collins (R),
Lisa Murkowski (R),
Gary Peters (D),
Tina Smith (D),
Elizabeth Warren (D),
Ron Wyden (D),
Last Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 07/18/2023)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/118th-congress/senate-bill/2362/all-info |
| BillText | https://www.congress.gov/118/bills/s2362/BILLS-118s2362is.pdf |
Loading...